Adage Capital Partners Gp, L.L.C. Ultragenyx Pharmaceutical Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.9 Billion
- Q4 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,183,081 shares of RARE stock, worth $46.4 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
1,183,081
Previous 1,525,741
22.46%
Holding current value
$46.4 Million
Previous $84.8 Million
41.27%
% of portfolio
0.09%
Previous 0.16%
Shares
22 transactions
Others Institutions Holding RARE
# of Institutions
345Shares Held
86.7MCall Options Held
675KPut Options Held
846K-
Vanguard Group Inc Valley Forge, PA10MShares$393 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$220 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.3MShares$168 Million0.57% of portfolio
-
State Street Corp Boston, MA2.72MShares$107 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.51MShares$98.4 Million0.01% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.74B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...